Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in: memo - Magazine of European Medical Oncology 3/2023

02.08.2023 | short review

Aggressive B cell lymphomas—highlights from ASH 2022

verfasst von: Michael Panny

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Summary

The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of diffuse large B cell lymphoma (DLBCL) as a one shot cancer. CD-19-targeted CART cell therapy, CD79b-targeted antibody drug conjugate polatuzumab vedotin, and CD 19 antibody tafasitamab in combination with lenalidomide are approved in relapsed/refractory (r/r) disease. Recently the bispecific CD20/CD3 antibody glofitamab received approval for third-line therapy and approval for other CD20/CD3 bispecific antibodies is expected soon. This short review is a personal selection of the clinically most relevant abstracts besides CART therapy regarding aggressive B cell lymphomas presented at the 2022 ASH meeting in San Diego.
Vorheriger Artikel Long-term survival and follow-up care after cancer in Austria
Nächster Artikel FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting
Literatur
1.
Illerhaus G et al. Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary cns lymphoma - results of an international randomized phase III trial (MATRix/IELSG43). Blood. 2022;140(suppl 2):LBA-3.
2.
Topp MS, et al. Glofitamab plus R‑CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B‑cell lymphoma (DLBCL): results from a phase Ib study. ASH 2022 abstract, Vol. 777. 2022.
3.
Abrisqueta P, et al. Subcutaneous Epcoritamab + R‑Dhax/C in patients with relapsed or refractory diffuse large B cell lymphoma eligible for autologous stem cell transplant: updated phase 1/2 results. ASH 2022 abstract, Vol. 443. 2022.
4.
Won-Seog K, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B‑cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM‑2. ASH 2022 Abtract, Vol. 444. 2022.
5.
Dickinson MJ, et al. Glofitamab for relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2022;387(24):2220–31.CrossRefPubMed
6.
Hutchings M, et al. Relapse is uncommon in patients with large B‑cell lymphoma who are in complete remission at the end of fixed-course Glofitamab treatment. ASH 2022 Abstract, Vol. 441. 2022.
7.
Kater AP, et al. Subcutaneous Epcoritamab in patients with richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). ASH 2022 abstract, Vol. 348. 2022.
8.
Duell J, et al. Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L‑MIND study. AACR 2023 abstract, Vol. CT022. 2023.
9.
Qualls D, et al. Tafasitamab and Lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): real world outcomes in a multicenter retrospective study. ASH 2022 abstract, Vol. 323. 2022.
Metadaten
Titel
Aggressive B cell lymphomas—highlights from ASH 2022
verfasst von
Michael Panny
Publikationsdatum
02.08.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00908-y

Weitere Artikel der Ausgabe 3/2023

memo - Magazine of European Medical Oncology 3/2023 Zur Ausgabe

short review

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

editorial

American Society of Hematology meeting update

short review

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

short review

Late complications after oncological therapy

short review

FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting

leading article

Emerging molecular drugs for the treatment of gastroesophageal tumors